Share on StockTwits

Exelixis (NASDAQ:EXEL) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 50,395,491 shares, a growth of 4.1% from the April 30th total of 48,433,036 shares, AnalystRatings.NET reports. Based on an average daily volume of 2,978,034 shares, the short-interest ratio is presently 16.9 days. Approximately 26.6% of the company’s shares are short sold.

A number of research firms have recently commented on EXEL. Analysts at Leerink Swann reiterated a “market perform” rating on shares of Exelixis in a research note on Friday, May 2nd. They now have a $4.50 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Exelixis in a research note on Friday, May 2nd. They now have a $4.00 price target on the stock. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. Exelixis presently has a consensus rating of “Buy” and a consensus target price of $6.70.

Exelixis (NASDAQ:EXEL) opened at 3.31 on Monday. Exelixis has a 1-year low of $3.02 and a 1-year high of $8.41. The stock has a 50-day moving average of $3.38 and a 200-day moving average of $5.49. The company’s market cap is $644.4 million.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $0.02. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.11 million. During the same quarter last year, the company posted ($0.24) earnings per share. Exelixis’s revenue was down 49.5% compared to the same quarter last year. Analysts expect that Exelixis will post $-1.56 EPS for the current fiscal year.

Exelixis, Inc (NASDAQ:EXEL) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.